Astellas acquires Potenza Therapeutics for $240.1 million
Astellas Pharma announced it exercised, and closed on its exclusive option to acquire Potenza Therapeutics on Dec. 13, 2018. This acquisition marks the successful outcome of a collaboration agreement entered into in 2015 to build a portfolio of novel immuno-oncology therapies. December 14, 2018